Navigation Links
FDA Expands Use of HIV Drug Isentress to Children and Adolescents
Date:12/21/2011

SILVER SPRING, MD., Dec. 21, 2011 /PRNewswire-USNewswire/ -- Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program, which allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients.

The program is designed to provide patients with earlier access to promising new drugs, but the company will be required to submit additional clinical information after approval to confirm the drug's clinical benefit.

"Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, M.D., M.P.H., director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. Because the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.

A single, multi-center clinical trial of 96 children and adolescents ages 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.

The most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping (insomnia) and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash. The drug should be discontinued if this occurs.

Isentress does not cure HIV infection. Patients must stay on continuous HIV therapy to control HIV infection and decrease HIV-related illnesses.

Isentress is made by Whitehouse Station, N.J.-based Merck & Co., Inc.

For more information:

FDA: HIV and AIDS Activities
http://www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/default.htm

FDA: Antiretroviral drugs used in the treatment of HIV infection
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm

CDC: HIV/AIDS
http://www.cdc.gov/hiv/default.htm

HHS: AIDS News and Resources
http://www.aids.gov/

AIDS Information
http://www.aidsinfo.nih.gov/

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits
2. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
3. Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools
4. Sony Expands Radiology Product Offerings with Full Line of Diagnostic Displays
5. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
6. Panasonic Expands on Hearing Instrument Lineup
7. Gaylord Sleep Medicine Expands Sleep Apnea Management Program
8. Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test for an Additional Investigational Cancer Immunotherapy Antigen
9. Free Statewide Rx Assistance Program Expands
10. AQUA® Technology Expands to Additional Digital Pathology Platform with Launch of Vectra™ 2 from Caliper Life Sciences, a Perkin-Elmer Company
11. Cincinnati Based Laboratory Furniture Regional Dealer and Representative Expands to Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017 Cognitive Computing for ... is allowing a previously unattainable level of personalized ... this ability, it is anticipated that the Global ... Billion by 2022. The growth of the market ... computing platforms, rising installation of cognitive computing software ...
(Date:2/21/2017)... Feb. 21, 2017  /PR Newswire/ -- UBM Medica,s ... announce the launch of Modern Retina ( ... retina specialists. Built upon the success of ... on the latest innovations in the areas of retinal ... management. By meeting current informational needs and filling existing ...
(Date:2/21/2017)... Scientists From Two Companies to Accelerate Development ... ... STEER, creator of advanced materials platform technologies that effectively ... pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, today announced a ... , a leading science & technology company, on ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... A new ... women are called back for additional examinations without sacrificing cancer detection, according to ... 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for ...
(Date:2/20/2017)... (PRWEB) , ... February 21, 2017 , ... Nancy ... offering readers a way to “ Getting Over the Bump in the Road ” ... and lessons learned on how to cope with the ups and downs experienced by ...
(Date:2/20/2017)... ... ... Silverado today is pleased to announce that it has entered into a management ... Alexandria, Virginia. The new community is expected to open its doors in the first ... three-story community with underground parking – located on King Street –will serve 66 people ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... 213-8818 , Orbita, Inc., a leading provider of innovative software for connected home ... patient engagement and optimizing care journey management for home healthcare. , Built ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... a cloud-based self-service technology that runs on the Posiflex XT-series of touch screen ... during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping ...
Breaking Medicine News(10 mins):